UBS lowered the firm’s price target on Elevance Health (ELV) to $555 from $605 and keeps a Buy rating on the shares post the Q3 report. The firm says Medicaid pressures are overwhelming the positive trends at the company’s commercial and Carelon units.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ELV:
Questions or Comments about the article? Write to editor@tipranks.com